<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00034697</url>
  </required_header>
  <id_info>
    <org_study_id>P02143</org_study_id>
    <nct_id>NCT00034697</nct_id>
    <nct_alias>NCT00030836</nct_alias>
  </id_info>
  <brief_title>Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell Lung Cancer (Study P02143)</brief_title>
  <official_title>A Phase II Study of Temozolomide (SCH 52365) in Subjects With Brain Metastasis From Non-Small-Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      Brain metastases from solid tumors are diagnosed in more than 300,000 patients annually.&#xD;
      Nonsmall cell lung cancer accounts for the majority of CNS mets. Treatment with whole brain&#xD;
      radiation and steroids will improve neurologic symptoms in about 50% of patients although&#xD;
      survival is short. This study will test the safety and efficacy of temozolomide in&#xD;
      combination with radiation therapy in the treatment of patients with brain mets form nonsmall&#xD;
      cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow Enrollment&#xD;
  </why_stopped>
  <start_date type="Actual">June 28, 2001</start_date>
  <completion_date type="Actual">January 30, 2003</completion_date>
  <primary_completion_date type="Actual">January 30, 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment type="Actual">24</enrollment>
  <condition>Metastases, Neoplasm</condition>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Brain Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic confirmation of non-small-cell lung cancer&#xD;
&#xD;
          -  Stable systemic disease&#xD;
&#xD;
          -  Maximum of one prior chemotherapy regimen for metastatic systemic disease&#xD;
&#xD;
          -  Radiotherapy for local control or palliative bony lesions is allowed&#xD;
&#xD;
          -  Karnofsky of greater than or equal to 70%&#xD;
&#xD;
          -  Adequate hematologic, renal and liver function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients eligible for surgery of the brain&#xD;
&#xD;
          -  Any previous chemotherapy for the brain metastasis&#xD;
&#xD;
          -  Chemotherapy within 4 weeks or previous temozolomide&#xD;
&#xD;
          -  Prior radiotherapy to the brain&#xD;
&#xD;
          -  Radiation therapy to greater than 50% of the bone marrow&#xD;
&#xD;
          -  Insufficient recovery from previous therapies&#xD;
&#xD;
          -  Active nonmalignant systemic disease&#xD;
&#xD;
          -  Inability to take oral medication&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  Non use of adequate contraceptive techniques, negative urine pregnancy test is&#xD;
             required&#xD;
&#xD;
          -  Known AIDS related illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>May 1, 2002</study_first_submitted>
  <study_first_submitted_qc>May 1, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2002</study_first_posted>
  <last_update_submitted>May 22, 2017</last_update_submitted>
  <last_update_submitted_qc>May 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brain mets</keyword>
  <keyword>non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis Links</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

